Skip to main content
. 2018 Jun 7;8(13):3611–3628. doi: 10.7150/thno.25613

Figure 2.

Figure 2

AI treatment enhances adaptive immune response in distant tumors. Groups for both flow cytometry and RNA-seq of NDL tumor mice at day 38 as treated in Figure 1A included: ablation-immunotherapy (AI), immunotherapy-alone (I), and no treatment control (NTC), where treated tumors are denoted as AI-T or I-T, and contralateral tumors are denoted as AI-C or I-C. (A-D) Flow cytometry results for (A) CD3+, (B) CD4+, (C) CD8+ T-cells, and (D) Interferon-gamma secreting CD8+ T-cells. AI (n=6 tumors), immunotherapy-alone (n=7 tumors), and NTC (n=4 tumors). * p <0.05, ** p <0.01, *** p <0.001, ****p<0.0001 (ANOVA with Fisher's LSD test). (E) RNA-seq results (samples as in Figure 1D) for genes associated with response to reactive oxygen species (ROS). All data plotted are mean ± SD. For RNA-seq results, bars represent significance of at least p < 0.01 as defined by CuffDiff.